NCT04985825View on ClinicalTrials.gov

Imgatuzumab in Patients With Advanced Cutaneous Squamous Cell Carcinoma

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

December 16, 2021

Primary Completion Date

August 17, 2022

Study Completion Date

August 17, 2022

Conditions
Cutaneous Squamous Cell Carcinoma
Interventions
DRUG

Imgatuzumab

Imgatuzumab administered as an intravenous infusion on Day 1 and Day 8 of the first 21-day cycle, and on Day 1 of each subsequent 14-day cycle.

Sponsors

Collaborators (1)

ICON plc
All Listed Sponsors
collaborator

ICON plc

INDUSTRY

lead

Pega-One S.A.S.

INDUSTRY